Pricing Log in Create free account

BridgeBio Oncology Therapeutics, Inc (BBOT) vs Compugen Ltd. (CGEN)

BridgeBio Oncology Therapeutics, Inc and Compugen Ltd. are both Biotechnology companies. Compugen Ltd. is the larger, with a market value of $185.7M against $163.6M — 1.1× the size. BridgeBio Oncology Therapeutics, Inc has negative trailing earnings, so its P/E is not meaningful; Compugen Ltd. trades at 5.2×. Compugen Ltd. has the higher net margin (47.6% vs 0.00%) and the higher return on invested capital (0.00% vs −127.7%). Across the 13 metrics below, Compugen Ltd. leads on 11 and BridgeBio Oncology Therapeutics, Inc on 2.

Valuation

Metric BBOT CGEN Biotechnology median
P/E n/m 5.16 10.60
P/S n/m 2.51 9.40
P/B 0.51 2.09 2.13
Price to free cash flow n/m 4.63 25.18
EV/EBITDA 0.31 1.99 0.66
EV/Sales n/m 0.81 9.02
Earnings yield (135.29%) 19.39% (32.88%)
Free cash flow yield (92.81%) 21.58% (23.13%)

Profitability

Metric BBOT CGEN Biotechnology median
Gross margin — 86.89% 68.51%
Operating margin 0.00% 40.94% 0.00%
Net margin 0.00% 47.55% 0.00%
Free cash flow margin 0.00% 54.10% 0.00%
Return on equity (252.10%) 47.85% (51.96%)
Return on assets (96.69%) 23.86% (46.06%)
Return on invested capital (127.66%) 0.00% 0.00%

Growth

Metric BBOT CGEN Biotechnology median
Revenue growth (TTM) — 234.18% 6.76%
EPS growth (last fiscal year) 99.93% 337.50% 29.88%
Revenue growth, 5-year CAGR — 105.20% 9.75%
Net income growth, 5-year CAGR — 0.00% 0.00%

Health

Metric BBOT CGEN Biotechnology median
Debt to equity 0.00 0.00 0.00
Current ratio 4.69 5.72 4.97
Net debt to EBITDA 2.93 (4.65) 1.01

Dividend

Metric BBOT CGEN Biotechnology median
Dividend yield — — 0.41%
Payout ratio — — —

Size

Metric BBOT CGEN Biotechnology median
Market cap 163.56m 185.67m 161.82m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack